ChristopherJ.LogothetisMD

Clinical Trials

• Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma Start of enrollment: 2000 Oct 01

  Completed

  Phase 1, Phase 2

• Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases Start of enrollment: 2003 May 01

  Completed

  Phase 2

• Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 Start of enrollment: 2003 May 01

  Completed

  Phase 2

• Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer Start of enrollment: 2007 Sep 01

  Terminated

  Phase 1

• BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets Start of enrollment: 2009 Mar 01

  Completed

  Phase 1

• Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Start of enrollment: 2009 Dec 01

  Completed

  Phase 2

• Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer Start of enrollment: 2010 Jul 09

  Terminated

  Phase 1, Phase 2

• Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies Start of enrollment: 2011 Mar 16

  Completed

  Phase 2

• Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 2013 Feb 05

  Active, not recruiting

  Phase 2

• Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide Start of enrollment: 2013 Oct 31

  Completed

  Phase 2

• SHIP (Selinexor in Hormone Insensitive Prostate Cancer) Start of enrollment: 2014 May 01

  Terminated

  Phase 2

• Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Start of enrollment: 2020 Mar 23

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance Start of enrollment: 2023 Mar 29

  Recruiting

  Roles: Principal Investigator, Contact

• Join now to see all